Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Teva
Deloitte
Argus Health
AstraZeneca
Boehringer Ingelheim
US Army
Mallinckrodt
McKesson

Generated: December 14, 2018

DrugPatentWatch Database Preview

Litigation Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

« Back to Dashboard

In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Docket ➤ Sign Up Date Filed 2015-04-27
Court District Court, S.D. New York Date Terminated
Cause 15:1 Antitrust Litigation (Monopolizing Trade) Assigned To Ronnie Abrams
Jury Demand Plaintiff Referred To Magistrate Judge Ronald L. Ell
Parties ACTAVIS PLC; AMERICAN SALES COMPANY, LLC; CESAR CASTILLO, INC.; MYLAN PHARMACEUTICALS, INC.; MYLAN, INC.; RANBAXY LABORATORIES LTD.; RANBAXY PHARMACEUTICALS, INC.; RANBAXY, INC.; SUN PHARMACEUTICAL INDUSTRIES LTD.; TAKEDA AMERICA HOLDINGS, INC.; TAKEDA DEVELOPMENT CENTER AMERICAS, INC.; TAKEDA PHARMACEUTICAL CO. LTD.; TAKEDA PHARMACEUTICALS U.S.A., INC.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.; WATSON LABORATORIES, INC.
Patents 4,687,777; 5,965,584; 6,150,383; 6,150,384; 6,166,042; 6,166,043; 6,172,090; 6,211,205; 6,271,243; 6,303,640; 6,329,404
Attorneys Adam R Lawton; Bradley J. Demuth; David S. Nalven; Gregory L. Skidmore; Gregory Thomas Arnold; John O'Quinn; Karen Hoffman Lent; Kristen Anne Johnson; Linda P. Nussbaum; Ross Lee Weiner; Stacey Anne Mahoney; Steven Craig Sunshine; Thane D. Scott; Thomas Matthew Sobol
Firms Hagens Berman Sobol Shapiro LLP; Hagens Berman Sobol Shapiro LLP (MA); Kirkland & Ellis LLP - NYC; Kirkland and Ellis LLP (Washington); Morgan, Lewis and Bockius LLP (NY); Munger Tolles & Olson LLP; Nussbaum Law Group, P.C.; Skadden, Arps, Slate, Meagher & Flom LLP (DC)
Link to Docket External link to docket
Small Molecule Drugs cited in In Re: Actos Direct Purchaser Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-04-27 1 after ACTOS’s drug substance patent—U.S. Patent No. 4,687,777 (the “’777 Patent”)—expired on January 17, …Meguro and Takeshi Fujita U.S. Patent No. 4,687,777 (the “’777 Patent”) entitled “Thiazolidinedione Derivatives…its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…manufacturer’s patents and patent information for accuracy or trustworthiness. In listing patents and patent information…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA External link to document
2016-01-07 54 drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January…and Takeshi Fujita U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) entitled “Thiazolidinedione…listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS External link to document
2016-01-28 62 U.S. Patent No. 4,687,777 (“’777 patent”), which expired in January 2011. Id. ¶ 158. Two patents claim…medications: U.S. Patent Nos. 5,965,584 (“’584 patent”) and 6,329,404 (“’404 patent”), both of which …traditional patent settlement, Teva (the alleged patent infringer) agreed to pay Takeda (the patent holder… the underlying patent infringement cases, or (2) the supposed weakness of the patent claims would have…relating to the ACTOS and ACTOplus met patent litigations and patent settlements are no different from those External link to document
2016-01-28 65 for and received U.S. Patent No. 4,687,777 covering pioglitazone. The ’777 patent has never been held …pioglitazone patents, including the ’777, ’584, and ’404 patents, as well as the method-of-use patents, for … and ’404 patents only as “method- of-use” patents for ACTOS and never as “product” patents, as shown…Takeda had not described the patents as “product” patents in its patent submission letters to the FDA…to list a patent. For each patent, pioneer drug companies are required to submit the patent if and only External link to document
2016-03-21 75 the United States Patent and Trade Office (“PTO”) issued U.S. Patent No. 4,687,777, containing claims…in the patent that covered the drug: a “drug” (drug substance) patent, a “drug product” patent, or a …not involve a patented method of use with respect to the method of use patent or patent claim.”). …Takeda's patent declarations for the ’584 and ’404 patents each stated that the patents claimed both…sponsor’s patent declaration describing relevant patent claims in Orange Book-listed patents.”113 The External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Citi
Chubb
Express Scripts
Teva
QuintilesIMS
Harvard Business School
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.